Drug intelligence / Profile preview

NST-27

Development stage: Preclinical
Lead developer: Novasenta
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NST-27 is an antibody-based therapeutic being developed by Novasenta for the treatment of inflammatory bowel disease (IBD) and other autoimmune diseases. The drug is designed to modulate pathogenic immune responses by targeting a novel, undisclosed immune cell target identified through Novasenta's discovery platform. As of the latest company updates, NST-27 is in the IND-enabling stage of development, representing one of the company's lead programs in its pipeline of therapies focused on the immune system and the tumor microenvironment.

Beyond the preview

Go deeper on NST-27.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NST-27.

Explore the full profile